An Evidence-Based Approach to Myeloma Bone Disease

Nicholas Bingham, Antonia Reale, Andrew Spencer

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Multiple myeloma is an incurable clonal plasma cell malignancy characterised by osteolytic bone lesions and the presence of a monoclonal immunoglobulin. The bone disease caused by myeloma is a major cause of morbidity with the related complications of pathological fractures, hypercalcaemia and bone pain affecting both quality of life and patient survival. The osteolytic lesions arise due to an imbalance of osteoclast and osteoblast function, arising from complex interactions between myeloma cells, bone marrow stromal cells and the bone marrow microenvironment. These advances in understanding of the pathophysiology have directly led to improvements in patient management and outcomes. Recent advances in myeloma bone disease are reviewed, including the role of novel and emerging therapies, and evidence-based management strategies for myeloma bone disease are discussed.

Original languageEnglish
Pages (from-to)109-118
Number of pages10
JournalCurrent Hematologic Malignancy Reports
Volume12
Issue number2
DOIs
Publication statusPublished - 1 Apr 2017

Keywords

  • Multiple myeloma
  • Myeloma bone disease
  • RANK/RANKL pathway

Cite this

@article{c76d876a59cc441d9cdd8016ea0ad123,
title = "An Evidence-Based Approach to Myeloma Bone Disease",
abstract = "Multiple myeloma is an incurable clonal plasma cell malignancy characterised by osteolytic bone lesions and the presence of a monoclonal immunoglobulin. The bone disease caused by myeloma is a major cause of morbidity with the related complications of pathological fractures, hypercalcaemia and bone pain affecting both quality of life and patient survival. The osteolytic lesions arise due to an imbalance of osteoclast and osteoblast function, arising from complex interactions between myeloma cells, bone marrow stromal cells and the bone marrow microenvironment. These advances in understanding of the pathophysiology have directly led to improvements in patient management and outcomes. Recent advances in myeloma bone disease are reviewed, including the role of novel and emerging therapies, and evidence-based management strategies for myeloma bone disease are discussed.",
keywords = "Multiple myeloma, Myeloma bone disease, RANK/RANKL pathway",
author = "Nicholas Bingham and Antonia Reale and Andrew Spencer",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s11899-017-0370-5",
language = "English",
volume = "12",
pages = "109--118",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer-Verlag London Ltd.",
number = "2",

}

An Evidence-Based Approach to Myeloma Bone Disease. / Bingham, Nicholas; Reale, Antonia; Spencer, Andrew.

In: Current Hematologic Malignancy Reports, Vol. 12, No. 2, 01.04.2017, p. 109-118.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - An Evidence-Based Approach to Myeloma Bone Disease

AU - Bingham, Nicholas

AU - Reale, Antonia

AU - Spencer, Andrew

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Multiple myeloma is an incurable clonal plasma cell malignancy characterised by osteolytic bone lesions and the presence of a monoclonal immunoglobulin. The bone disease caused by myeloma is a major cause of morbidity with the related complications of pathological fractures, hypercalcaemia and bone pain affecting both quality of life and patient survival. The osteolytic lesions arise due to an imbalance of osteoclast and osteoblast function, arising from complex interactions between myeloma cells, bone marrow stromal cells and the bone marrow microenvironment. These advances in understanding of the pathophysiology have directly led to improvements in patient management and outcomes. Recent advances in myeloma bone disease are reviewed, including the role of novel and emerging therapies, and evidence-based management strategies for myeloma bone disease are discussed.

AB - Multiple myeloma is an incurable clonal plasma cell malignancy characterised by osteolytic bone lesions and the presence of a monoclonal immunoglobulin. The bone disease caused by myeloma is a major cause of morbidity with the related complications of pathological fractures, hypercalcaemia and bone pain affecting both quality of life and patient survival. The osteolytic lesions arise due to an imbalance of osteoclast and osteoblast function, arising from complex interactions between myeloma cells, bone marrow stromal cells and the bone marrow microenvironment. These advances in understanding of the pathophysiology have directly led to improvements in patient management and outcomes. Recent advances in myeloma bone disease are reviewed, including the role of novel and emerging therapies, and evidence-based management strategies for myeloma bone disease are discussed.

KW - Multiple myeloma

KW - Myeloma bone disease

KW - RANK/RANKL pathway

UR - http://www.scopus.com/inward/record.url?scp=85028253175&partnerID=8YFLogxK

U2 - 10.1007/s11899-017-0370-5

DO - 10.1007/s11899-017-0370-5

M3 - Review Article

VL - 12

SP - 109

EP - 118

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 2

ER -